**Mini Review**
Volume 15:01, 2024

Journal of AIDS & Clinical Research

ISSN: 2155-6113 Open Access

# Bones under Siege: Unravelling the Complexities of HIV-associated Bone Disease

**Nicholas Sebastian***

*Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, 26504 Rio, Greece*

## Abstract

This paper offers a comprehensive overview of the World Health Organization's (WHO) strategic endeavors to enhance worldwide access to vaccines and fortify immunization programs. By analyzing WHO's initiatives, partnerships, and policy frameworks, the study explores the organization's role in promoting equitable vaccine distribution and bolstering immunization efforts to achieve optimal public health outcomes.

**Keywords:** Vaccination access • Immunization programs • Vaccine equity

## Introduction

Since the emergence of HIV/AIDS in the 1980s, remarkable strides have been made in treatment and management, transforming what was once a death sentence into a chronic condition. However, as people with HIV live longer, new challenges emerge and one such challenge is HIV-associated bone disease. This condition, characterized by decreased bone mineral density, increased fracture risk and other skeletal abnormalities, presents a multifaceted puzzle for researchers and clinicians alike. In this article, we delve into the complexities of HIV-associated bone disease, exploring its underlying mechanisms, clinical manifestations, diagnostic approaches and management strategies [1].

## Literature Review

The pathogenesis of HIV-associated bone disease is multifactorial, involving a complex interplay of factors such as chronic inflammation, immune dysregulation, antiretroviral therapy (ART), traditional risk factors for osteoporosis and direct effects of the virus on bone cells [2]. Chronic inflammation, driven by persistent immune activation and elevated levels of proinflammatory cytokines, plays a central role in bone loss by stimulating osteoclast activity and inhibiting osteoblast function. Furthermore, certain antiretroviral drugs, particularly tenofovir-based regimens, have been implicated in bone loss through various mechanisms, including renal dysfunction and alterations in vitamin D metabolism [3].

HIV-associated bone disease often presents clinically as osteopenia, osteoporosis, or osteonecrosis, with affected individuals at increased risk of fragility fractures, particularly of the hip and spine. However, diagnosing bone disease in people with HIV can be challenging due to overlapping risk factors, such as aging, low body weight, smoking and substance abuse. Traditional bone mineral density measurements using dual-energy X-ray absorptiometry (DXA) may underestimate fracture risk in this population, necessitating the development of more accurate diagnostic tools tailored to the unique characteristics of HIV-associated bone disease [4].

***Address for Correspondence:** Nicholas Sebastian, Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, 26504 Rio, Greece; E-mail: nicholas.sebastian@gmail.com*



**Received:** 22 January, 2024, Manuscript No. jar-24-133856; **Editor assigned:** 24 January, 2024, PreQC No. P- 133856; **Reviewed:** 09 February, 2024, QC No. Q-133856; **Revised:** 15 February, 2024, Manuscript No. R- 133856; **Published:** 22 February, 2024, DOI: 10.37421/2155-6113.2024.15.982

Management of HIV-associated bone disease requires a multifaceted approach aimed at addressing both traditional and HIV-specific risk factors. Lifestyle modifications, including smoking cessation, adequate nutrition, weight-bearing exercise and moderation of alcohol and substance use, are fundamental to preserving bone health. Additionally, optimizing ART regimens to minimize bone toxicity while maintaining virologic suppression is essential. This may involve switching to alternative antiretroviral agents with a more favorable bone profile or supplementing with agents such as vitamin D and calcium to mitigate bone loss. For individuals at high fracture risk, pharmacologic interventions such as bisphosphonates or denosumab may be considered, although their safety and efficacy in people with HIV require further study [5,6].

## Discussion

HIV-associated bone disease presents a multifaceted challenge, intertwining the effects of the virus itself, antiretroviral therapy (ART) and associated factors like chronic inflammation and lifestyle behaviors. The skeletal system is not merely a structural framework but a dynamic organ susceptible to HIV-related complications, including osteoporosis, osteopenia and avascular necrosis.

One key player in bone health disruption is the chronic inflammation induced by HIV infection. This inflammatory milieu stimulates bone resorption and inhibits bone formation, leading to accelerated bone loss. Additionally, certain ART medications, particularly tenofovir-based regimens, have been implicated in bone mineral density reduction, further exacerbating skeletal fragility.

However, the landscape of HIV-associated bone disease is nuanced. While some studies suggest a direct link between specific antiretrovirals and bone loss, others emphasize the pivotal role of traditional risk factors such as aging, smoking, low body mass index and vitamin D deficiency. Moreover, the interplay between HIV, ART and bone health is influenced by genetic predispositions and HIV-related comorbidities, complicating the understanding and management of bone disease in this population.

Addressing HIV-associated bone disease requires a comprehensive approach. Clinicians must integrate routine screening for bone mineral density and fracture risk assessment into HIV care protocols. Lifestyle modifications, including smoking cessation, optimizing nutritional status and promoting physical activity, are crucial components of bone health management. Additionally, selecting ART regimens with favorable bone profiles and considering adjunctive therapies such as vitamin D supplementation or bisphosphonates may mitigate bone loss in susceptible individuals.

As our understanding of HIV-associated bone disease evolves, continued research efforts are essential to elucidate its pathophysiology, optimize diagnostic strategies and develop targeted interventions. By unravelling the

complexities of bone health in the context of HIV, we can strive to improve the quality of life and long-term outcomes for individuals living with HIV.

## Conclusion

HIV-associated bone disease represents a complex and evolving challenge in the management of HIV/AIDS. As the population of people living with HIV continues to age, the burden of bone disease is likely to increase, highlighting the need for comprehensive screening, prevention and management strategies. By unravelling the underlying mechanisms and addressing both traditional and HIV-specific risk factors, clinicians can better care for the skeletal health of individuals living with HIV, improving their quality of life and reducing the burden of fragility fractures. Continued research efforts are essential to refine diagnostic tools, optimize treatment approaches and ultimately mitigate the impact of HIV-associated bone disease on this vulnerable population.

## Acknowledgement

None.

## Conflict of Interest

None.

## References

1. McComsey, Grace A., Pablo Tebas, Elizabeth Shane and Michael T. Yin, et al. "Bone disease in HIV infection: a practical review and recommendations for HIV care providers." *Clin Infect Dis* 51 (2010): 937-946.
2. Goh, S.S.L., Pauline Siew Mei Lai, Alexander Tong Boon Tan and Sasheela Ponnampalavanar, et al. "Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors." *Osteoporos* 29 (2018): 595-613.
3. Meng, Weiqing, Meiling Chen, Yangzi Song and Huan Zhang, et al. "Prevalence and risk factors of low bone mineral density in HIV/AIDS patients: A Chinese cross-sectional study." *J Acquir Immune Defic Syndr* 90 (2022): 360-368.
4. Cotter, Eoin J., Herbert Shi Ming Ip, William G. Powderly and Peter P. Doran, et al. "Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation." *BMC Musculoskelet Disord* 9 (2008): 1-12.
5. Beaupere, Carine, Marie Garcia, Jerome Larghero and Bruno Fève, et al. "The HIV proteins T at and N ef promote human bone marrow mesenchymal stem cell senescence and alter osteoblastic differentiation." *Aging Cell* 14 (2015): 534-546.
6. Cotter, Eoin J., Andrea P. Malizia, Nicholas Chew and William G. Powderly, et al. "HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development." *AIDS Res Hum Retroviruses* 23 (2007): 1521-1530.

**How to cite this article:** Sebastian, Nicholas. “Bones under Siege: Unravelling the Complexities of HIV-associated Bone Disease.” *J AIDS Clin Res* 15 (2024): 982.